EL7.AI
StocksMedium•17 November 2026•
3 min read

Palatin Reports $361,802 in First-Quarter Revenue as Losses and Funding Pressures Mount

Key Facts

1Collaboration and licensing revenue was $361,802, compared with $8,847,550 in the comparable quarter.
2The company posted a net loss of $5,057,511, compared with net income of $4,677,534.
3Cash and cash equivalents were $3,740,424 on September 30, 2026, down from $7,492,014 on June 30, 2026.
4Expenses for the obesity programs were $2,053,949, compared with $970,629 in the comparable period.

Palatin Technologies reported first-quarter fiscal 2026 results on November 17, recording collaboration and licensing revenue of $361,802 for the quarter ended September 30. The statements showed a net loss of $5,057,511, compared with net income of $4,677,534 in the same quarter a year earlier. The announcement was made at 07:30 Eastern time. The quarter's revenue consisted solely of reimbursement for research and development services performed under the company's agreement with Boehringer Ingelheim. Management said additional funding would be required to carry out planned development activities and fund operations.

Collaboration and licensing revenue was $8,847,550 in the comparable period, a level that included upfront payments and contractual milestone payments, according to the company's filing with the U.S. Securities and Exchange Commission. The difference in revenue sources means the year-over-year comparison includes prior payments that did not recur in the current quarter. Current-period revenue consisted of reimbursements for research and development services related to the Boehringer Ingelheim agreement. The company posted a basic and diluted loss per share of $1.29, after diluted earnings per share of $4.26 in the comparable period. These figures put the quarter's results in the context of a shift from income and profitability to a loss and lower revenue.

Research and development expenses rose to $3,383,743, compared with $2,525,766 a year earlier. The company attributed the increase mainly to spending on its obesity programs targeting melanocortin receptors. Expenses for those programs were $2,053,949, compared with $970,629 in the same quarter. The filing said most of the spending increase was related to preliminary preclinical work in preparation for an investigational drug application, as well as optimization of an oral small-molecule drug candidate. This reflects a greater allocation of resources to candidate development as quarterly revenue declined.

The company said its long-acting peptide program targets the MC4R receptor while seeking to reduce or eliminate hyperpigmentation, an effect associated with activation of the MC1R receptor. Chief Executive Carl Spana described the weekly-dose results as having "demonstrated significant efficacy in preclinical models." On November 16, the company presented preclinical data indicating lower body weight and food consumption in experimental models. These results are preliminary and do not represent findings from a clinical trial in humans. The work is part of the obesity programs that the company said were the main contributor to higher research and development expenses.

Palatin used net cash of $3,741,589 in operating activities during the quarter, compared with $1,619,382 in the comparable period. The company attributed the higher cash use to lower receipts under the Boehringer Ingelheim agreement and higher research and development and general and administrative expenses. Cash and cash equivalents stood at $3,740,424 at the end of September, down from $7,492,014 on June 30, 2026. Management said substantial doubt exists about the company's ability to continue as a going concern for one year after the financial statements were issued. It added that additional funding is needed to cover operations and carry out planned development activities.

The company is targeting the first half of 2027 to begin a Phase 1 study of the long-acting peptide candidate, with initial data targeted for the second half of the year. For the oral small-molecule candidate, the company is targeting the second half of 2027 to begin a Phase 1 study. Initial clinical data for the program are targeted for the first half of 2028. Palatin is scheduled to discuss the results and development activities on a conference call and webcast on November 17, 2026, at 11:00 a.m. Eastern time. The timelines tie program progress to the availability of additional funding, in light of management's going-concern warning.

Open on chart